Author: Anna Smith

EU Marketing Authorisation change for Maviret

The authorisation shortens the treatment period from from 12 to eight weeks.

The extra lives saved between 2010 and 2018 means that the NHS has met its own ambitious 20% target two years ahead of the 2020 deadline.

With the outbreak at “critical juncture”, analysts are saying Gilead’s remdesivir stands a 50% chance of success as a vaccine.

Another £140 million will then be used to bolster the services further from 2021 onwards.

Key issues mentioned were complex working processes between pharmacies and GP practices, handling prescriptions and management of patient records.

PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN